本計畫延續上年度已完成四十四株肺癌細胞株之基因圖譜與細胞侵襲能力資料，是目前涵蓋最多帶有EGFR突變之肺癌細胞株資料庫，預計將再建立肺癌胞外泌體的蛋白質體與轉錄體資料，透過生物資訊的整合性分析發掘具潛力之癌症血液診斷標誌。藉由分析胞外泌體的轉錄體(microRNA, miRNA)與蛋白質體，有助於瞭解肺癌胞外泌體的病理意義，且結合腫瘤基因突變、轉移能力與抗藥性相關的重要癌症特性，有其一定的前瞻性，可以提供做為肺癌診斷與治療的參考與加速非侵入式診斷試劑開發。 ;We have established the genomic profile, TKI response and invasion ability of 44 lung cancer cell lines in the previous year. This project will generate the exosome database of lung cancer cell lines. The database will include the transcriptomic profile by RNAseq and miRNAseq and proteomic profile by mass. Integration of omics data and phenotype data by bioinformatics analysis will find potential biomarkers for validation with lung cancer patients’ blood samples. Profiling of exosomal signatures will help us better understand the pathological mechanism in lung cancer. Combination with important clinical issues such as cancer mutation status, metastasis and drug resistance will provide the reference for lung cancer diagnosis and treatment. It is prospective study for development of non-invasive diagnostic reagents.
